Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03452228 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT03452228 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT03452228, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.
Interventions
- DRUG Placebo
- DRUG evinacumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2018-06-07 |
| Est. Completion | 2020-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03452228
The ClinicalTrials.gov registry entry for NCT03452228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03452228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03452228 about?
NCT03452228 is a clinical study titled "Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis". The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.
What is the current status of trial NCT03452228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2018-06-07. Estimated completion is 2020-07-23.
What interventions are being tested in trial NCT03452228?
The interventions under investigation include: Placebo (DRUG), evinacumab (DRUG).
Who is sponsoring clinical trial NCT03452228?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.